Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development
A Volz, G Sutter - Advances in virus research, 2017 - Elsevier
Abstract Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation
vaccine against smallpox and serves as a potent vector system for development of new …
vaccine against smallpox and serves as a potent vector system for development of new …
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
B Moss - Proceedings of the National Academy of Sciences, 1996 - National Acad Sciences
Vaccinia virus, no longer required for immunization against smallpox, now serves as a
unique vector for expressing genes within the cytoplasm of mammalian cells. As a research …
unique vector for expressing genes within the cytoplasm of mammalian cells. As a research …
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
Y Peng, SL Felce, D Dong, F Penkava, AJ Mentzer… - Nature …, 2022 - nature.com
Abstract NP105–113-B* 07: 02-specific CD8+ T cell responses are considered among the
most dominant in SARS-CoV-2-infected individuals. We found strong association of this …
most dominant in SARS-CoV-2-infected individuals. We found strong association of this …
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
TR Fuerst, EG Niles, FW Studier… - Proceedings of the …, 1986 - National Acad Sciences
DNA coding for bacteriophage T7 RNA polymerase was ligated to a vaccinia virus
transcriptional promoter and integrated within the vaccinia virus genome. The recombinant …
transcriptional promoter and integrated within the vaccinia virus genome. The recombinant …
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Modified vaccinia Ankara (MVA), a highly attenuated vaccinia virus strain that has been
safety tested in humans, was evaluated for use as an expression vector. MVA has multiple …
safety tested in humans, was evaluated for use as an expression vector. MVA has multiple …
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles
J Zhou, XY Sun, DJ Stenzel, IH Frazer - Virology, 1991 - Elsevier
A recombinant vaccinia virus termed pLC201 VV was designed to coexpress the Li and L2
late genes of human papillomavirus type 16 (HPV16). Synthesis of the Li and L2 proteins …
late genes of human papillomavirus type 16 (HPV16). Synthesis of the Li and L2 proteins …
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
M Murakami, M Hibi, N Nakagawa, T Nakagawa… - Science, 1993 - science.org
The biological functions of interleukin-6 (IL-6) are mediated through a signal-transducing
component of the IL-6 receptor, gp130, which is associated with the ligand-occupied IL-6 …
component of the IL-6 receptor, gp130, which is associated with the ligand-occupied IL-6 …
Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme
CA Ray, RA Black, SR Kronheim, TA Greenstreet… - Cell, 1992 - cell.com
Cowpox virus effectively inhibits inflammatory responses against viral infection in the chick
embryo. This study demonstrates that one of the viral genes necessary for this inhibition, the …
embryo. This study demonstrates that one of the viral genes necessary for this inhibition, the …
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.
JW Yewdell, JR Bennink, GL Smith… - Proceedings of the …, 1985 - National Acad Sciences
Influenza A virus-specific cytotoxic T lymphocytes (CTL) capable of lysing cells infected with
any influenza A virus (" cross-reactive CTL") constitute a major portion of the host CTL …
any influenza A virus (" cross-reactive CTL") constitute a major portion of the host CTL …
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals
The threat of avian influenza A (H5N1) infection in humans remains a global health concern.
Current influenza vaccines stimulate antibody responses against the surface glycoproteins …
Current influenza vaccines stimulate antibody responses against the surface glycoproteins …